Logo image of HCAT

HEALTH CATALYST INC (HCAT) Stock Fundamental Analysis

NASDAQ:HCAT - Nasdaq - US42225T1079 - Common Stock - Currency: USD

4.1  +0.12 (+3.02%)

After market: 4.07 -0.03 (-0.73%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to HCAT. HCAT was compared to 37 industry peers in the Health Care Technology industry. HCAT may be in some trouble as it scores bad on both profitability and health. HCAT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year HCAT was profitable.
In the past year HCAT had a positive cash flow from operations.
HCAT had negative earnings in each of the past 5 years.
In the past 5 years HCAT reported 4 times negative operating cash flow.
HCAT Yearly Net Income VS EBIT VS OCF VS FCFHCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

HCAT's Return On Assets of -8.09% is fine compared to the rest of the industry. HCAT outperforms 64.86% of its industry peers.
Looking at the Return On Equity, with a value of -19.03%, HCAT is in the better half of the industry, outperforming 62.16% of the companies in the same industry.
Industry RankSector Rank
ROA -8.09%
ROE -19.03%
ROIC N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
HCAT Yearly ROA, ROE, ROICHCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

HCAT's Gross Margin of 46.25% is on the low side compared to the rest of the industry. HCAT is outperformed by 64.86% of its industry peers.
In the last couple of years the Gross Margin of HCAT has declined.
The Profit Margin and Operating Margin are not available for HCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
HCAT Yearly Profit, Operating, Gross MarginsHCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HCAT has been increased compared to 1 year ago.
Compared to 5 years ago, HCAT has more shares outstanding
Compared to 1 year ago, HCAT has a worse debt to assets ratio.
HCAT Yearly Shares OutstandingHCAT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HCAT Yearly Total Debt VS Total AssetsHCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.26, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
HCAT has a Altman-Z score of -1.26. This is comparable to the rest of the industry: HCAT outperforms 40.54% of its industry peers.
HCAT has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of HCAT (0.41) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z -1.26
ROIC/WACCN/A
WACC9.08%
HCAT Yearly LT Debt VS Equity VS FCFHCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.43 indicates that HCAT should not have too much problems paying its short term obligations.
HCAT has a Current ratio (1.43) which is comparable to the rest of the industry.
HCAT has a Quick Ratio of 1.43. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
HCAT has a Quick ratio of 1.43. This is comparable to the rest of the industry: HCAT outperforms 48.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
HCAT Yearly Current Assets VS Current LiabilitesHCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.67% over the past year.
Looking at the last year, HCAT shows a small growth in Revenue. The Revenue has grown by 3.60% in the last year.
The Revenue has been growing by 14.63% on average over the past years. This is quite good.
EPS 1Y (TTM)86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)3.6%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.02%

3.2 Future

Based on estimates for the next years, HCAT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.57% on average per year.
HCAT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.38% yearly.
EPS Next Y7.34%
EPS Next 2Y24.01%
EPS Next 3Y37.14%
EPS Next 5Y28.57%
Revenue Next Year9.12%
Revenue Next 2Y9.46%
Revenue Next 3Y9.75%
Revenue Next 5Y11.38%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HCAT Yearly Revenue VS EstimatesHCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
HCAT Yearly EPS VS EstimatesHCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 14.64, the valuation of HCAT can be described as correct.
HCAT's Price/Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 91.89% of the companies in the same industry.
HCAT is valuated rather cheaply when we compare the Price/Earnings ratio to 28.79, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 13.64 indicates a correct valuation of HCAT.
Based on the Price/Forward Earnings ratio, HCAT is valued cheaply inside the industry as 94.59% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HCAT to the average of the S&P500 Index (21.38), we can say HCAT is valued slightly cheaper.
Industry RankSector Rank
PE 14.64
Fwd PE 13.64
HCAT Price Earnings VS Forward Price EarningsHCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCAT Per share dataHCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
HCAT's earnings are expected to grow with 37.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.99
PEG (5Y)N/A
EPS Next 2Y24.01%
EPS Next 3Y37.14%

More info and screens

0

5. Dividend

5.1 Amount

HCAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEALTH CATALYST INC

NASDAQ:HCAT (4/25/2025, 8:12:47 PM)

After market: 4.07 -0.03 (-0.73%)

4.1

+0.12 (+3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners89.34%
Inst Owner Change3.79%
Ins Owners2.43%
Ins Owner Change13.65%
Market Cap287.86M
Analysts80
Price Target7.55 (84.15%)
Short Float %4.38%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.35%
Min EPS beat(2)-46.95%
Max EPS beat(2)-29.75%
EPS beat(4)2
Avg EPS beat(4)11.79%
Min EPS beat(4)-46.95%
Max EPS beat(4)75.51%
EPS beat(8)6
Avg EPS beat(8)577.85%
EPS beat(12)10
Avg EPS beat(12)402.75%
EPS beat(16)14
Avg EPS beat(16)313.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.97%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)-1.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.7%
Min Revenue beat(4)-2.06%
Max Revenue beat(4)-0.79%
Revenue beat(8)2
Avg Revenue beat(8)-0.85%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)7
Avg Revenue beat(16)-0.2%
PT rev (1m)-15.83%
PT rev (3m)-35.14%
EPS NQ rev (1m)2147.06%
EPS NQ rev (3m)-95.4%
EPS NY rev (1m)-20.7%
EPS NY rev (3m)-25.18%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-4.61%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-2.22%
Valuation
Industry RankSector Rank
PE 14.64
Fwd PE 13.64
P/S 0.94
P/FCF N/A
P/OCF 19.77
P/B 0.79
P/tB 14.84
EV/EBITDA N/A
EPS(TTM)0.28
EY6.83%
EPS(NY)0.3
Fwd EY7.33%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.21
OCFY5.06%
SpS4.37
BVpS5.2
TBVpS0.28
PEG (NY)1.99
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.09%
ROE -19.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.25%
FCFM N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.58%
Cap/Sales 5.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -1.26
F-Score5
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y7.34%
EPS Next 2Y24.01%
EPS Next 3Y37.14%
EPS Next 5Y28.57%
Revenue 1Y (TTM)3.6%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.02%
Revenue Next Year9.12%
Revenue Next 2Y9.46%
Revenue Next 3Y9.75%
Revenue Next 5Y11.38%
EBIT growth 1Y36.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.95%
EBIT Next 3Y45.11%
EBIT Next 5Y33.62%
FCF growth 1Y96.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y144.01%
OCF growth 3YN/A
OCF growth 5YN/A